Exicure, Inc.(XCUR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XCUR Exicure, Inc.

Trading 05-05 10:07:26 EDT

3.34

+0.09

+2.77%

High3.51	Low3.20	Vol8.92K
Open3.51	D1 Closing3.25	Amplitude9.60%
Mkt Cap21.29M	Tradable Cap7.78M	Total Shares6.37M
T/O29.62K	T/O Rate0.38%	Tradable Shares2.33M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XCUR","market":"US","secType":"STK","nameCN":"Exicure, Inc.","latestPrice":3.34,"timestamp":1777989990286,"preClose":3.25,"halted":0,"volume":8915,"delay":0,"changeRate":0.027692307692307648,"floatShares":2327862,"shares":6373869,"eps":-0.785441,"marketStatus":"Trading","change":0.09,"latestTime":"05-05 10:07:26 EDT","open":3.512,"high":3.512,"low":3.2,"amount":29616.2335455,"amplitude":0.096,"askPrice":3.34,"askSize":100,"bidPrice":3.22,"bidSize":13,"shortable":3,"etf":0,"ttmEps":-0.785441,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1778011200000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":3.25,"postHourTrading":{"tag":"盘后","latestPrice":3.25,"preClose":3.25,"latestTime":"18:46 EDT","volume":63,"amount":203.49,"timestamp":1777934798544,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":5.906477},"requestUrl":"/m/hq/s/XCUR","defaultTab":"news","newsList":[{"id":"2629071752","title":"BRIEF-Exicure announces co-development agreement with Adbiotech for Burixafor (Gpc-100)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629071752","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629071752?lang=en_us&edition=fundamental","pubTime":"2026-04-23 07:57","pubTimestamp":1776902248,"startTime":"0","endTime":"0","summary":"BRIEF-Exicure announces co-development agreement with Adbiotech for Burixafor (Gpc-100)April 22 (Reuters) - Exicure Inc XCUR.O:EXICURE ANNOUNCES CO-DEVELOPMENT AGREEMENT WITH ADBIOTECH FOR BURIXAFOR (","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nTUA70QX5C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XCUR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629071296","title":"Exicure partners with Adbiotech to co-develop Burixafor combination therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2629071296","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629071296?lang=en_us&edition=fundamental","pubTime":"2026-04-23 07:54","pubTimestamp":1776902079,"startTime":"0","endTime":"0","summary":"Exicure entered a co-development agreement with Korea-based Adbiotech to evaluate combination therapies using Burixafor .Collaboration targets sickle cell disease, acute myeloid leukemia, solid tumors.Adbiotech will run in vivo studies, support preclinical validation, translational research.Exicure will supply Burixafor, lead clinical and regulatory strategy.Parties may advance selected programs into IND-enabling studies, clinical trials, subject to a subsequent definitive agreement.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL6ZqPK8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BN0W2W23.USD","LU2210150020.SGD","SG9999014013.SGD","SG9999014039.USD","BK4585","SG9999014021.USD","XCUR","IE00BKPKM429.USD","NDAQ","IE00B64PRP62.GBP","BK4588","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","LU2095319765.USD","LU0314104364.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","LU2210149790.SGD","BK4112","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629071250","title":"Exicure Announces Co-Development Agreement With Adbiotech for Burixafor (Gpc-100)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629071250","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629071250?lang=en_us&edition=fundamental","pubTime":"2026-04-23 07:54","pubTimestamp":1776902061,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nTUA70QX5C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XCUR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626214885","title":"Exicure names Young Seung Ko chief operating officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2626214885","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626214885?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:17","pubTimestamp":1775852251,"startTime":"0","endTime":"0","summary":"Exicure appointed Young Seung Ko as chief operating officer effective April 9, 2026.Ko previously served as CEO and director of AGEDB Technology Ltd. from September 2022 to March 2025.He also held role as director of global operations at Bitnine Global from October 2020 to September 2024.Audit committee leadership shifted, with Dongho Lee appointed chair.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL5Yv5TJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XCUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624568408","title":"Exicure Inc - Announces Settlement of Stockholder Derivative Action per March 18, 2026 Stipulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2624568408","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624568408?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:03","pubTimestamp":1775160222,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nFWN40L10Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XCUR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624747684","title":"Exicure reaches settlement in stockholder derivative litigation, adopts governance reforms","url":"https://stock-news.laohu8.com/highlight/detail?id=2624747684","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624747684?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:01","pubTimestamp":1775160109,"startTime":"0","endTime":"0","summary":"Exicure reached settlement in consolidated stockholder derivative litigation in US District Court for Northern District of Illinois.Agreement requires corporate governance reforms to be implemented, maintained for four years.Claims alleged board-level failures in internal controls tied to study data collection, analysis, reporting, public disclosures, causing reputational, financial harm.Settlement includes USD 0.7 million in plaintiffs’ attorneys’ fees, paid by insurers, subject to court approval.Settlement hearing is set for June 2, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL8Ngvh4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","NDAQ","BK4588","SG9999014005.SGD","LU2095319765.USD","IE00BKPKM429.USD","SG9999014039.USD","LU2210149790.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00B3QW5Z07.USD","XCUR","BK4139","IE00BN0W2W23.USD","BK4585","BK4112","LU0314104364.USD","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014013.SGD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622038808","title":"Exicure board changes; Sangjin Yeo resigns from board and audit committee effective March 27, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2622038808","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622038808?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:41","pubTimestamp":1774644072,"startTime":"0","endTime":"0","summary":"The company said the resignation was not due to any disagreement over its operations, policies, or practices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL44NzCZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XCUR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622800296","title":"Exicure Q4 EPS $(0.22) Up From $(3.39) YoY.","url":"https://stock-news.laohu8.com/highlight/detail?id=2622800296","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622800296?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:35","pubTimestamp":1774470930,"startTime":"0","endTime":"0","summary":"Exicure (NASDAQ:XCUR) reported quarterly losses of $(0.22) per share. This is a 93.51 percent increase over losses of $(3.39) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51470045/exicure-q4-eps-0-22-up-from-3-39-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Exicure Q4 EPS $(0.22) Up From $(3.39) YoY.","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTEC","BK4139","MNQmain","SQQQ","IYW","QYLG","TQQQ","JEPQ","NQmain","QDTE","QQQJ","QQQY","NVIW.SI","QID","GPIQ","PSQ","QLD","QQQE",".IXIC","XCUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622040330","title":"Press Release: Exicure, Inc. Reports Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622040330","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622040330?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:18","pubTimestamp":1774469880,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., March 25, 2026  -- Exicure, Inc.  releases the following financial results for the year ended December 31, 2025.Research and Development (R&D) Expense: Research and development expenses were $3.3 million for the year ended December 31, 2025, as compared to $0 for the year ended December 31, 2024. The increase of $3.3 million reflects R&D activities incurred following the acquisition of GPCR Therapeutics USA Inc. , which conducts research operations. Immediately prior to closing the acquisition of GPCR USA, the Company recorded no research or development expenses.Loss from sale or disposal of property and equipment: The Company recognized a $90,000 loss from GPCR USA's sale of fixed assets.Going Concern: Management believes that the Company's existing cash and cash equivalents is not sufficient to continue to fund operations. The Company has already engaged in significant cost reductions, and its ability to further cut costs and extend the Company's operating runwa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XCUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621754367","title":"Top News Today: Stocks Slide, Treasury Yields Rise Amid Oil Shock","url":"https://stock-news.laohu8.com/highlight/detail?id=2621754367","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621754367?lang=en_us&edition=fundamental","pubTime":"2026-03-21 04:42","pubTimestamp":1774039320,"startTime":"0","endTime":"0","summary":"STOCKS: Stocks slid, with the S&P 500 closing down 6.8% from its recent peak, as oil futures tested recent highs, exacerbating fears about the economic implications of war in Iran.TREASURYS: Treasury yields added to recent gains, and the policy-sensitive two-year yield completed its sharpest three-week increase since 2023.COMMODITIES: Brent oil futures rose 3.3% to $112.19 a barrel, capping an 8.8% gain for the week. U.S.-traded oil futures rose 2.3% to $98.32, cutting their losses for the week to 39 cents, and hovering near multiyear highs.Tech Exec Accused of Smuggling High-End Nvidia Chips to China. \"A shift in radio station programming strategies, coupled with challenging economic realities, has made it impossible to continue the service,\" the email said. \"We are sharing this announcement now to fulfill our commitments to our radio partners and affiliates, which require advance notice of the service's conclusion.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4120","BK4096","BK4023","INLX","XCUR","RELV","TBRG","NFE","BK4563","ANNX","BK4167","BK4144","BK4097","CYCN","HSDT","MTEX","BK4110","SKYX","TWAV","TE","BK4138","LFT","MBOT","BK4600","BK4082","EFOI","PAVM","GNE","BK4081","LNZA","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621575125","title":"Top News Today/Canada: Retail Sales Rose 1.1% in January","url":"https://stock-news.laohu8.com/highlight/detail?id=2621575125","media":"Dow Jones","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621575125?lang=en_us&edition=fundamental","pubTime":"2026-03-21 04:30","pubTimestamp":1774038600,"startTime":"0","endTime":"0","summary":"Consumers in Canada showed signs of resilience in the early months of the year despite mounting struggles for the economy and ahead of the surge in prices at the pump that threatens to take a bite out of consumption.Retail sales in the first month of 2026 rose 1.1% from the month before to a seasonally adjusted C$70.71 billion, Statistics Canada said. An advance tally of receipts indicates sales in February were up 0.9%.If the estimate for last month holds, it would mark the first back-to-back increase for retailers in almost a year after choppy trade for much of 2025. That would represent a tailwind for the economy this quarter, amid a raft of otherwise gloomy signals for the country.Producer price inflation in Canada cooled somewhat last month, though an increase in energy prices hinted at early signs of pressure from the conflict in the Middle East.Compared with a year earlier, the producer-price index climbed 5.4%.The French train maker said Friday that the contract with provincial","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","BK4110","BK4096","BK4144","BK4139","CYCN","XCUR","MBOT","LFT","BK4081","BK4563","EFOI","BK4120","INLX","GNE","MTEX","BK4138","NFE","BK4082","BK4183","ANNX","PAVM","LNZA","RELV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612968774","title":"Exicure Inc - Appoints Gyuyeob Lee as Interim CFO - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2612968774","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612968774?lang=en_us&edition=fundamental","pubTime":"2026-02-18 06:32","pubTimestamp":1771367548,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nFWN3ZD1BG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XCUR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612879496","title":"Exicure Inc - Andy Yoo Resigns as CEO and President of Exicure - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2612879496","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612879496?lang=en_us&edition=fundamental","pubTime":"2026-02-18 06:32","pubTimestamp":1771367548,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nFWN3ZD1BG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XCUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612495059","title":"Exicure Inc. Appoints Jung Soo Kim as CEO and Gyuyeob Lee as Interim CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2612495059","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612495059?lang=en_us&edition=fundamental","pubTime":"2026-02-18 06:25","pubTimestamp":1771367154,"startTime":"0","endTime":"0","summary":"Exicure Inc. has appointed Jung Soo Kim as Chief Executive Officer and President, and Gyuyeob Lee as Interim Chief Financial Officer and Secretary, effective February 11, 2026. They replace Andy Yoo and Seung Ik Baik, who resigned from their respective positions effective February 9, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL8DPh1W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XCUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610679196","title":"Exicure Inc. Appoints Three New Directors as CEO and CFO Resign","url":"https://stock-news.laohu8.com/highlight/detail?id=2610679196","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610679196?lang=en_us&edition=fundamental","pubTime":"2026-02-11 05:26","pubTimestamp":1770758786,"startTime":"0","endTime":"0","summary":"Exicure Inc. announced that Andy Yoo and Seung Ik Baik have resigned from their roles as Chief Executive Officer and Chief Financial Officer, respectively, effective February 9, 2026. Additionally, Andy Yoo, Seung Ik Baik, and Aejin Hwang have resigned from the Board of Directors. The board has appointed Jung Kyu Ham, Jung Soo Kim, and Gyeung Seog Cheon as new directors, with Mr. Cheon also joining the audit committee. The CEO and CFO positions will remain vacant until new appointments are made.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL3C98Bm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XCUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609374199","title":"Exicure kündigt erfolgreiche Phase-2-Studie mit Burixafor zur schnellen Stammzellmobilisierung bei Multiplem Myelom und Lymphom an","url":"https://stock-news.laohu8.com/highlight/detail?id=2609374199","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609374199?lang=en_us&edition=fundamental","pubTime":"2026-02-05 20:00","pubTimestamp":1770292826,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via GlobeNewswire  on February 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL7XbNjq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","NDAQ","BK4585","SG9999014005.SGD","XCUR","LU0314104364.USD","SG9999014039.USD","SG9999014021.USD","BK4139","BK4112","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2210150020.SGD","LU2095319765.USD","BK4588","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609374110","title":"Exicure Reports Phase 2 Success for Burixafor in Rapid Stem Cell Mobilization for Transplant Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2609374110","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609374110?lang=en_us&edition=fundamental","pubTime":"2026-02-05 20:00","pubTimestamp":1770292826,"startTime":"0","endTime":"0","summary":"Exicure Inc. has announced the publication of results from a Phase 2 clinical study evaluating burixafor, a highly selective CXCR4 inhibitor, in the journal Annals of Hematology. The study assessed burixafor in combination with granulocyte colony-stimulating factor  in patients with multiple myeloma, non-Hodgkin's lymphoma, and Hodgkin disease undergoing autologous stem cell transplantation. The results showed that 92% of participants met the primary endpoint of collecting at least 5.0 × 10 CD34+ cells/kg within two leukapheresis sessions, with half achieving the target in a single session. Burixafor demonstrated rapid stem cell mobilization, with peak CD34+ cell counts occurring within one hour of administration, and was generally well tolerated. Additionally, Exicure recently completed another Phase 2 study evaluating burixafor in combination with G-CSF and propranolol in multiple myeloma patients. Positive topline data from this study were presented at the American Society of Hemato","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL8W2r61:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU0314104364.USD","BK4139","SG9999014005.SGD","BK4588","NDAQ","SG9999014013.SGD","BK4585","IE00BKPKM429.USD","LU2210150020.SGD","IE00B64PRP62.GBP","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014021.USD","XCUR","LU2210149790.SGD","SG9999014039.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605417795","title":"Exicure Achieves Milestone in Collaboration with GPCR Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2605417795","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605417795?lang=en_us&edition=fundamental","pubTime":"2026-01-23 05:29","pubTimestamp":1769117392,"startTime":"0","endTime":"0","summary":"Exicure Inc. has achieved the first milestone under its License and Collaboration Agreement with GPCR Therapeutics Inc., following the completion of a Phase 2 clinical trial for its novel stem cell mobilizer. As part of the agreement, Exicure will make a $1 million milestone payment to GPCR Therapeutics Inc. This collaboration focuses on the development of Burixafor , a small molecule CXCR4 inhibitor, and the milestone completion also activates a future sublicensing income-sharing arrangement between the two companies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Se","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL2B9pdd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XCUR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605101748","title":"Exicure to present data from burixafor Phase 2 trial at 2026 Tandem Meetings","url":"https://stock-news.laohu8.com/highlight/detail?id=2605101748","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605101748?lang=en_us&edition=fundamental","pubTime":"2026-01-21 20:15","pubTimestamp":1768997740,"startTime":"0","endTime":"0","summary":"Exicure (XCUR) announced that it will present a poster at the upcoming 2026 Tandem Meetings Transplantation & Cellular Therapy Meetings of the Amer...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/exicure-to-present-data-from-burixafor-phase-2-trial-at-2026-tandem-meetings-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/exicure-to-present-data-from-burixafor-phase-2-trial-at-2026-tandem-meetings-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XCUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605562101","title":"Exicure Reports Positive Phase 2 Results for Burixafor in Multiple Myeloma Stem Cell Mobilization","url":"https://stock-news.laohu8.com/highlight/detail?id=2605562101","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605562101?lang=en_us&edition=fundamental","pubTime":"2026-01-21 20:00","pubTimestamp":1768996826,"startTime":"0","endTime":"0","summary":"Exicure Inc. announced that it will present data from its open-label, multicenter Phase 2 trial evaluating burixafor in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation at the 2026 Tandem Meetings, taking place February 4-7, 2026, in Salt Lake City, UT. The poster presentation will feature previously reported results, highlighting that 89.7% of patients met the primary endpoint for successful stem cell mobilization using a regimen of burixafor, propranolol, and G-CSF. The data indicate that the combination provided reliable mobilization and a favorable safety profile. The presentation is scheduled for February 5, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the origi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDLbNcWGJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00B64PRP62.GBP","BK4585","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","NDAQ","SG9999014013.SGD","SG9999014021.USD","LU2210150020.SGD","XCUR","SG9999014005.SGD","BK4112","IE00BGHQF748.EUR","SG9999014039.USD","LU0314104364.USD","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.exicuretx.com","stockEarnings":[{"period":"1week","weight":-0.0871},{"period":"1month","weight":-0.2243},{"period":"3month","weight":-0.215},{"period":"6month","weight":-0.2073},{"period":"1year","weight":-0.6971},{"period":"ytd","weight":-0.4004}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0948},{"period":"3month","weight":0.0413},{"period":"6month","weight":0.0597},{"period":"1year","weight":0.2669},{"period":"ytd","weight":0.0529}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Exicure, Inc. does not have significant operations. previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.050352},{"month":2,"riseRate":0.375,"avgChangeRate":-0.040535},{"month":3,"riseRate":0.375,"avgChangeRate":-0.031749},{"month":4,"riseRate":0.375,"avgChangeRate":-0.028338},{"month":5,"riseRate":0.25,"avgChangeRate":-0.025781},{"month":6,"riseRate":0.25,"avgChangeRate":-0.042251},{"month":7,"riseRate":0.25,"avgChangeRate":-0.052633},{"month":8,"riseRate":0.25,"avgChangeRate":-0.062697},{"month":9,"riseRate":0.25,"avgChangeRate":-0.030428},{"month":10,"riseRate":0.25,"avgChangeRate":-0.064735},{"month":11,"riseRate":0.5,"avgChangeRate":0.997962},{"month":12,"riseRate":0.5,"avgChangeRate":-0.072048}],"exchange":"NASDAQ","name":"Exicure, Inc.","nameEN":"Exicure, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Exicure, Inc.(XCUR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Exicure, Inc.(XCUR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Exicure, Inc.,XCUR,Exicure, Inc.股票,Exicure, Inc.股票老虎,Exicure, Inc.股票老虎国际,Exicure, Inc.行情,Exicure, Inc.股票行情,Exicure, Inc.股价,Exicure, Inc.股市,Exicure, Inc.股票价格,Exicure, Inc.股票交易,Exicure, Inc.股票购买,Exicure, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Exicure, Inc.(XCUR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Exicure, Inc.(XCUR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}